Replies to post #430970 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

That is an assumptions not indicated by the Anavex PR statement.

A-273 on the other hand , reduces amyloid with almost no brain shrinkage.

The Anavex PR said:

validated biomarkers of amyloid beta pathology, plasma Aß42/40 ratio increased significantly (P = 0.048), demonstrating strong anti-amyloid effects of blarcamesine in Alzheimer’s disease patients, while MRI revealed significant reduction in brain volume loss, including whole brain (P = 0.0005), comparing treatment to placebo.

The Aß42/40 ratio is considered a biomarker in Alzheimer's research and clinical assessments. It's used to help diagnose Alzheimer's disease and monitor disease progression, as changes in this ratio can provide insights into the accumulation of amyloid plaques in the brain. We can't conclude from present information that the reduction in the Aß42/40 ratio is correlated with decomposition and removal of pre-existing amyloid plaques in the brain.

MRI scan cannot be used to detect of amyloid plaques in the brain, this why PET scan are used. If perhaps in the OLE study Anavex are using PET scans to see if amyloid plaques are in indeed being reduced, then something new and amazing would be happening.